CVS Restores Zepbound Coverage and Adds Eli Lilly’s New Obesity Pill, Reshaping the GLP-1 Market for 10 Million Patients
The GLP-1 drug wars just entered a new chapter. CVS Health announced it will restore coverage of Eli Lilly’s weight-loss injection Zepbound across its commercial formularies…


